Clinical Trial Update: UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating UB-VV400 in combination with rapamycin for relapsed or refractory B-cell malignancies, currently recruiting. The condition lis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large B-cell Lymphoma

Drugs mentioned

• Rapamycin (sirolimus)
• UB-VV400

Snippet

Sponsor: Nanjing IASO Biotechnology Co., Ltd. | Conditions: Large B-cell Lymphoma | Phase 1 | Status: RECRUITING